The narrowing losses and extended cash runway into Q2 2027 reduce near-term dilution risk. Upcoming catalysts include mid-2027 pivotal data from PiNACLE trial supporting a potential BLA filing. Monitor progress in PiNACLE-H2H and LYL273 dose escalation for further de-risking.
Price Chart
Executive Summary
Lyell Immunopharma reported its Q4 and full-year 2025 financial results, highlighted by reduced net losses compared to the prior year, ongoing pivotal trials for ronde-cel in lymphoma, clinical progress with LYL273 in colorectal cancer, and a $50 million equity tranche closing. The company has $247.2 million in cash as of year-end 2025, with runway into Q2 2027.
Key Financial Metrics
Key Facts
- Net loss narrowed to $140.7M in Q4 2025 from $191.9M in Q4 2024; full-year loss decreased to $274.4M from $343.0M in 2024.
- Cash, cash equivalents, and marketable securities were $247.2M as of December 31, 2025, excluding $50M raised in March 2026.
- Patient dosing has commenced in the Phase 3 head-to-head PiNACLE-H2H trial of ronde-cel vs. axi-cel or liso-cel in 2L large B-cell lymphoma.
- Seven new patients treated with LYL273 in mCRC since acquisition, with no dose-limiting toxicity and escalation to Dose Level 3.
- Ronde-cel showed 93% best overall response rate and 76% complete response rate in 29 efficacy-evaluable patients in the 3L+ setting.
- Second $50M tranche of $100M private placement closed in March 2026 after clinical milestone achievement.
- Smital Shah appointed Chief Financial and Business Officer in March 2026.
Financial Impact
Reduced operating expenses and improved cash efficiency: non-GAAP net loss decreased to $33.1M (Q4) and $144.8M (full-year) from $45.9M and $159.5M in 2024. R&D spend decreased on a non-GAAP basis despite LYL273 acquisition costs.
Risk Factors
- High cash burn relative to market cap; future equity offerings likely if trials extend or fail.
- Clinical trial execution risk in large randomized Phase 3 trial (PiNACLE-H2H).
- LYL273 is early-stage with limited data; dose escalation could reveal toxicity.
- Forward-looking statements carry significant uncertainty; no revenue from product candidates yet.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255090 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | Insider Cluster | $15.49 $10.53 | ▼ −32.02% | ▼ −33.00% | $9.26 (−40.22%) |
Jul 22, 2026 10w ago | EFFECT | $12.84 $15.76 | ▲ +22.74% | ▲ +19.84% | $9.26 (−27.88%) |
Jun 15, 2026 15w ago | Insider Cluster | $12.44 $13.40 | ▲ +7.72% | ▲ +7.52% | $9.26 (−25.56%) |
Jun 12, 2026 16w ago | Press Release | $13.50 $15.01 | ▲ +11.19% | ▲ +9.41% | $9.26 (−31.41%) |
Jun 8, 2026 16w ago | Press Release | $12.31 $14.04 | ▲ +14.05% | ▲ +12.42% | $9.26 (−24.78%) |
Jun 4, 2026 17w ago | Press Release | $11.97 $14.04 | ▲ +17.29% | ▲ +15.43% | $9.26 (−22.64%) |
Apr 24, 2026 23w ago | DEFA14A | $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $9.26 (−59.06%) |
Apr 15, 2026 24w ago | EFFECT | $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $9.26 (−61.16%) |
Apr 3, 2026 26w ago | S-3 | $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $9.26 (−57.31%) |
Mar 12, 2026 29w ago | Press Release | $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $9.26 (−56.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access